Niacin Modulates Immune Responses in a Phase I Dose-Escalation Clinical Trial of Newly Diagnosed Glioblastoma
This study provides Class IV evidence that niacin dose escalation modulates immune response in patients with glioblastoma treated with standard of care, including maximal safe resection, concurrent radiation and temozolomide, and adjuvant temozolomide administration. This is a Class IV study because it is an open-label trial with no blinding or comparison group.
Authors
- Candice C. Poon (ORCID: https://orcid.org/0000-0002-8990-8431)
- Aito Ueno (ORCID: https://orcid.org/0000-0002-9967-7200)
- Reza Mirzaei (ORCID: https://orcid.org/0000-0002-2393-2770)
- Gloria Roldan-Urgoiti
- Kathleen M. Hagen
- Paula A. de Robles
- V. Wee Yong
- Claudia Silva
- Susobhan Sarkar
Institutions
- University of Alberta (CA)
- University of Calgary (CA)
- Alberta Children's Hospital (CA)
- Institute of Cancer Research (CA)
- Alberta Cancer Foundation (CA)
- Ontario Brain Institute (CA)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1212/nxi.0000000000200530
- Primary Topic
- Sirtuins and Resveratrol in Medicine
- Type
- article
- Field-Weighted Citation Impact
- 0.00